BFC Planning, Inc.’s Rigel Pharmaceuticals RIGL Stock Holding History

BFC Planning, Inc.’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$48.2K	Sell	1,000 -2,000	-67%	-$86.8K	﹤0.01%	1575
2026 Q2	$117K	Buy	+3,000	New	+$92.5K	﹤0.01%	1167
2026 Q1	–	Sell	-47	Closed	-$2.01K	–	3273
2025 Q4	$2.01K	Sell	47 -12	-20%	-$452	﹤0.01%	2635
2025 Q3	$1.67K	Sell	59 -1,000	-94%	-$29.9K	﹤0.01%	2524
2025 Q2	$19.8K	Buy	1,059 +59	+6%	+$1.12K	﹤0.01%	1499
2025 Q1	$18K	Buy	+1,000	New	+$20.3K	﹤0.01%	1506

Other funds holding RIGL

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

BFC Planning, Inc.'s RIGL Position: Q3 2026 in Review

BFC Planning, Inc. reduced its Rigel Pharmaceuticals (RIGL) stake by 67% in Q3 2026, selling an estimated $86.8K and leaving 1,000 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

BFC Planning, Inc. first reported a position in RIGL in Q1 2025 and has held it in 6 quarters since. The position peaked at $117K in Q2 2026. 127 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

BFC Planning, Inc. held 1,000 shares of Rigel Pharmaceuticals worth $48.2K as of Q3 2026.
BFC Planning, Inc. sold 2,000 Rigel Pharmaceuticals shares in Q3 2026, an estimated $86.8K.
Rigel Pharmaceuticals made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q3 2026, its #1575 holding.
BFC Planning, Inc. first reported a position in Rigel Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
BFC Planning, Inc.'s Rigel Pharmaceuticals position peaked at $117K in Q2 2026.
127 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on BFC Planning, Inc.'s 13F filing for Q3 2026, filed 13 Nov 2026.